CDEK
← All drugs Report issue

gx-i7

Recombinant proteinexperimental

Clinical trial activity

14 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2016 (NCT02860715)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • gx-i7

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06344715Phase 1Oct 17, 2022Seoul National University, SL BIGEN
NCT05280457Phase 2Apr 30, 2022Yonsei University
NCT05191784Phase 2Jan 26, 2022Genexine, Inc.
NCT04730427Phase 1Jan 31, 2021Genexine, Inc.
NCT04810637Phase 2Nov 1, 2020Genexine, Inc.
NCT04065087Phase 1/Phase 2 (Phase 2)Aug 22, 2019Genexine, Inc.
NCT03752723Phase 1/Phase 2 (Phase 2)Dec 31, 2018Genexine, Inc., Merck
NCT03733587Phase 1/Phase 2 (Phase 2)Oct 17, 2018Genexine, Inc.
NCT03619239Phase 1/Phase 2 (Phase 2)Jun 20, 2018Genexine, Inc.
NCT03478995Phase 1Mar 5, 2018Catholic University of Korea, Genexine, Inc., University of Ulsan, Yonsei University
NCT03206138N/AMay 30, 2017Catholic University of Korea, Genexine, Inc.
NCT03144934Phase 1Feb 10, 2017Genexine, Inc.
NCT02860715Phase 1Jul 1, 2016Genexine, Inc., Seoul National University
NCT04289155N/A—Genexine, Inc.
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Genexine, Inc.For profit121132016
Catholic University of KoreaAcademic/Hospital2122017
Seoul National UniversityAcademic/Hospital2012016
Yonsei UniversityAcademic/Hospital2122018
MerckFor profit1012018
SL BIGENFor profit1112022
University of UlsanAcademic/Hospital1012018
7 organizations
Page 1 / 1